Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:LLY
  • CUSIP: 53245710
  • Web: www.lilly.com
  • Market Cap: $89.52 billion
  • Outstanding Shares: 1,056,300,000
Average Prices:
  • 50 Day Moving Avg: $82.14
  • 200 Day Moving Avg: $81.04
  • 52 Week Range: $64.18 - $86.72
  • Trailing P/E Ratio: 40.73
  • Foreward P/E Ratio: 19.26
  • P/E Growth: 1.69
Sales & Book Value:
  • Annual Revenue: $21.59 billion
  • Price / Sales: 4.15
  • Book Value: $13.28 per share
  • Price / Book: 6.38
  • Annual Dividend: $2.08
  • Dividend Yield: 2.5%
  • EBIDTA: $5.64 billion
  • Net Margins: 10.13%
  • Return on Equity: 26.64%
  • Return on Assets: 10.35%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.24%
  • Quick Ratio: 0.86%
  • Average Volume: 3.56 million shs.
  • Beta: 0.35
  • Short Ratio: 2.62

Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Monday, June 19th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) announced its earnings results on Tuesday, April, 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.96 by $0.02. The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and Company had a net margin of 10.13% and a return on equity of 26.64%. Eli Lilly and Company's revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.83 earnings per share. View Eli Lilly and Company's Earnings History.

When will Eli Lilly and Company make its next earnings announcement?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Eli Lilly and Company.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, April, 25th. The company provided earnings per share (EPS) guidance of $4.05-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.10. The company issued revenue guidance of $21.8-22.3 billion, compared to the consensus revenue estimate of $22.10 billion.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

16 equities research analysts have issued 12 month target prices for Eli Lilly and Company's shares. Their predictions range from $73.00 to $100.00. On average, they anticipate Eli Lilly and Company's share price to reach $88.67 in the next year. View Analyst Ratings for Eli Lilly and Company.

What are analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

  • 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
  • 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and Company's key competitors?

Who are Eli Lilly and Company's key executives?

Eli Lilly and Company's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer
  • Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
  • Michael J. Harrington, Senior Vice President, General Counsel
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Lilly Endowment Inc. (11.76%), Fisher Asset Management LLC (0.28%), Beutel Goodman & Co Ltd. (0.24%), US Bancorp DE (0.22%), Bank of Montreal Can (0.14%) and Hexavest Inc. (0.13%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., NN Investment Partners Holdings N.V., Bedrijfstakpensioenfonds Voor DE Media PNO, Hexavest Inc., OLD National Bancorp IN, Exxonmobil Investment Management Inc. TX, Grassi Investment Management and Park National Corp OH. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC, Beutel Goodman & Co Ltd., Mn Services Vermogensbeheer B.V., National Pension Service, Atalanta Sosnoff Capital LLC, Handelsbanken Fonder AB and BKD Wealth Advisors LLC. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and Company's stock price today?

One share of Eli Lilly and Company stock can currently be purchased for approximately $84.75.

MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  630 (Vote Outperform)
Underperform Votes:  455 (Vote Underperform)
Total Votes:  1,085
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $88.67 (4.62% upside)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Deutsche Bank AGReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/13/2017Jefferies Group LLCReiterated RatingBuy$93.00 -> $96.00LowView Rating Details
7/4/2017Citigroup Inc.Reiterated RatingBuy$100.00LowView Rating Details
7/4/2017Barclays PLCBoost Price TargetOverweight$85.00 -> $90.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy -> Buy$92.00HighView Rating Details
4/29/2017BMO Capital MarketsReiterated RatingUnderperform$71.00 -> $73.00LowView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
4/19/2017Credit Suisse GroupReiterated RatingOutperform$87.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00MediumView Rating Details
4/17/2017Cowen and CompanyBoost Price TargetOutperform$85.00 -> $95.00MediumView Rating Details
4/17/2017Morgan StanleyDowngradeOverweight -> Equal Weight$82.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
2/4/2016Berenberg BankBoost Price TargetBuy$105.00 -> $106.00N/AView Rating Details
12/22/2015Bank of America CorporationReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Eli Lilly and Company (NYSE:LLY)
Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)
Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017$1.05N/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
2017 EPS Consensus Estimate: $4.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.04$1.06$1.05
Q3 20172$1.00$1.04$1.02
Q4 20172$1.05$1.07$1.06
(Data provided by Zacks Investment Research)


Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
Next Dividend:9/8/2017
Annual Dividend:$2.08
Dividend Yield:2.45%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:100.48% (Trailing 12 Months of Earnings)
50.49% (Based on This Year's Estimates)
47.27% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.47%
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.00View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.01View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Eli Lilly and Company (NYSE:LLY)
Latest Headlines for Eli Lilly and Company (NYSE:LLY)
americanbankingnews.com logoZacks: Brokerages Anticipate Eli Lilly and Company (LLY) Will Post Quarterly Sales of $5.59 Billion
www.americanbankingnews.com - July 20 at 10:35 AM
nasdaq.com logoIs a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings? - Nasdaq
www.nasdaq.com - July 20 at 12:24 AM
finance.yahoo.com logoIs a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
finance.yahoo.com - July 20 at 12:24 AM
americanbankingnews.com logoFY2020 EPS Estimates for Eli Lilly and Company Lowered by SunTrust Banks (LLY)
www.americanbankingnews.com - July 19 at 3:46 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Expected to Post Earnings of $1.03 Per Share
www.americanbankingnews.com - July 19 at 12:16 AM
americanbankingnews.com logoSunTrust Banks Equities Analysts Cut Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
www.americanbankingnews.com - July 18 at 9:54 AM
americanbankingnews.com logoEli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 18 at 9:09 AM
americanbankingnews.com logoEli Lilly and Company (LLY) Price Target Raised to $91.00
www.americanbankingnews.com - July 17 at 7:15 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 17 at 6:41 PM
americanbankingnews.com logoZacks Investment Research Upgrades Eli Lilly and Company (LLY) to Buy
www.americanbankingnews.com - July 17 at 3:28 PM
finance.yahoo.com logoAmgen FDA Letter Isn't A Surprise (Or A Concern), Says Jefferies
finance.yahoo.com - July 17 at 12:57 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Eli Lilly and Company's FY2017 Earnings (NYSE:LLY)
www.americanbankingnews.com - July 17 at 9:36 AM
finance.yahoo.com logoNovartis stocks drug cabinet with "Big-3" arthritis blockbusters
finance.yahoo.com - July 15 at 5:53 AM
americanbankingnews.com logoFY2019 Earnings Forecast for Eli Lilly and Company Issued By Jefferies Group (NYSE:LLY)
www.americanbankingnews.com - July 14 at 3:19 PM
streetinsider.com logoEli Lilly & Co. (LLY): Tweaking Estimates Ahead of Numerous Catalsyts - Jefferies - StreetInsider.com
www.streetinsider.com - July 14 at 6:11 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire
finance.yahoo.com - July 14 at 6:11 AM
finance.yahoo.com logoLilly Settles Patent Litigation on Cialis with Generic Firms
finance.yahoo.com - July 14 at 6:11 AM
americanbankingnews.com logoEli Lilly and Company (LLY) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - July 13 at 9:02 PM
seekingalpha.com logoEli Lilly's Abemaciclib: Better Than Competition In Breast Cancer ... - Seeking Alpha
seekingalpha.com - July 13 at 6:25 AM
streetinsider.com logoEli Lilly & Co. (LLY) Reports Settlement Agreement in US Cialis Patent Litigation - StreetInsider.com
www.streetinsider.com - July 13 at 6:25 AM
marketwatch.com logoEli Lilly settlement will result in Cialis patent expiring as early as 2018, rather than 2020 - MarketWatch
www.marketwatch.com - July 13 at 6:25 AM
prnewswire.com logoEli Lilly and Company to Present More Than 40 Abstracts at the ... - PR Newswire (press release)
www.prnewswire.com - July 13 at 6:25 AM
americanbankingnews.com logoAnalysts Issue Forecasts for Eli Lilly and Company's Q2 2017 Earnings (LLY)
www.americanbankingnews.com - July 12 at 7:29 AM
finance.yahoo.com logoLilly's Breast Cancer Drug Gets Priority Review Status by FDA
finance.yahoo.com - July 12 at 2:22 AM
americanbankingnews.com logoLeerink Swann Comments on Eli Lilly and Company's FY2018 Earnings (NYSE:LLY)
www.americanbankingnews.com - July 11 at 2:42 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 11 at 10:04 AM
finance.yahoo.com logoFDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
finance.yahoo.com - July 11 at 12:20 AM
finance.yahoo.com logoRenowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment
finance.yahoo.com - July 11 at 12:20 AM
finance.yahoo.com logoLilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK
finance.yahoo.com - July 11 at 12:20 AM
finance.yahoo.com logoFDA Cranks Up Its Review of Eli Lilly's Advanced Breast Cancer Drug
finance.yahoo.com - July 11 at 12:20 AM
finance.yahoo.com logo[$$] U.K. Court Says Generics Infringe on Lilly’s Alimta Patents
finance.yahoo.com - July 10 at 12:04 AM
finance.yahoo.com logoWhat’s News: Business & Finance
finance.yahoo.com - July 10 at 12:04 AM
News IconUK Supreme Court rules in Eli Lilly's favor in drug dispute - Business ... - Business Insider
www.businessinsider.com - July 9 at 7:04 PM
streetinsider.com logoEli Lilly & Co. (LLY) Announces Favorable Ruling on Alimta Vitamin Regimen Patents from UK Supreme Courts - StreetInsider.com
www.streetinsider.com - July 9 at 7:04 PM
finance.yahoo.com logoUK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents
finance.yahoo.com - July 8 at 12:15 PM
finance.yahoo.com logo[$$] U.K. Court Says Generics Infringe on Lilly's Alimta Patents
finance.yahoo.com - July 8 at 12:15 PM
marketbeat.com logoUK Supreme Court rules in Eli Lilly's favor in drug dispute
marketbeat.com - July 7 at 10:32 AM
finance.yahoo.com logoLilly and Purdue University Announce Strategic Research Collaboration
finance.yahoo.com - July 7 at 6:57 AM
finance.yahoo.com logoLilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement
finance.yahoo.com - July 7 at 6:57 AM
americanbankingnews.com logoInvestors Purchase High Volume of Put Options on Eli Lilly and Company (NYSE:LLY)
www.americanbankingnews.com - July 5 at 7:24 AM
finance.yahoo.com logoIncyte & Lilly's Olumiant Gets Marketing Approval in Japan
finance.yahoo.com - July 4 at 6:18 PM
fool.com logoBetter Buy: Pfizer Inc. vs. Eli Lilly and Company
www.fool.com - July 1 at 2:23 PM
finance.yahoo.com logoThe Crazy Math Behind Drug Prices
finance.yahoo.com - June 30 at 1:08 AM
finance.yahoo.com logoBlink Health Giving Away $10 Million Worth Of Free Diabetes Medications
finance.yahoo.com - June 28 at 8:00 PM
abcnews.go.com logoMerck says new type of cholesterol drug worked in big study - ABC News
abcnews.go.com - June 27 at 11:28 PM
finance.yahoo.com logoTanezumab Receives FDA Fast Track Designation
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logoLilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logoPfizer Fueling Growth Of Competitors' Pipelines
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logo[$$] Merck Cholesterol Drug Could Help Unlock Value
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logoBetter Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
finance.yahoo.com - June 27 at 6:27 PM



Eli Lilly and Company (LLY) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff